Provectus Biopharmaceuticals Inc. Extends For Additional 60 Days Memorandum Of Understanding With Sinopharm-China State Institute Of Pharmaceutical Industry And Sinopharm A-Think Pharmaceutical Co., Ltd

KNOXVILLE, TN--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), today announced that it had extended for an additional 60 days its Memorandum of Understanding with with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group. The extension was the only change to the agreement, and the MOU is now in force through July 15, 2015.

Help employers find you! Check out all the jobs and post your resume.

Back to news